Hypothesis

Calibrated mTORC1 activity in colonic epithelial cells regulates the flux through the one-carbon metabolism pathway, thereby modulating S‑adenosylmethionine (SAM) levels and the activity of DNA methyltransferases (DNMTs). This creates a measurable, tissue‑specific DNA methylation signature that tracks the biological age of the gut and distinguishes healthy anabolic states from pathological hyperproliferation.

Mechanistic Rationale

1. mTORC1 controls methionine uptake and MAT2A expression – mTORC1 signaling upregulates the expression of methionine transporters (e.g., SLC7A5) and the enzyme methionine adenosyltransferase 2A (MAT2A), which converts methionine to SAM. When mTORC1 is chronically active, as seen in aged gut, methionine influx and SAM synthesis are elevated, potentially leading to hypermethylation at specific CpG sites.
2. SAM availability directly influences DNMT activity – DNMTs use SAM as a methyl donor; fluctuations in SAM concentration alter methylation kinetics without changing DNMT protein levels. Thus, mTOR‑driven shifts in SAM provide a rapid, metabolic link to the epigenome.
3. Feedback via autophagy and one‑carbon cycle enzymes – mTORC1 inhibition stimulates autophagy, which can degrade key enzymes of the folate cycle (e.g., MTHFD1), reducing SAM regeneration and promoting a hypomethylated state. This bidirectional control creates a tunable rheostat rather than a switch.
4. Site‑specific susceptibility – Certain colonic CpG islands, particularly those in promoters of genes governing stem cell proliferation (e.g., LGR5, ASCL2) and barrier function (e.g., MUC2), contain motifs that are sensitive to SAM fluctuations, making them candidate biomarkers.

Testable Predictions

• Prediction 1: Pharmacological inhibition of mTORC1 with rapamycin in aged mice will decrease colonic SAM levels and produce a predictable loss of methylation at a defined set of CpG sites, correlating with improved villus height and stem cell viability.
• Prediction 2: Constitutive activation of mTORC1 (e.g., via intestinal‑specific TSC1 knockout) will increase SAM and cause hypermethylation at the same CpG sites, accompanied by stem cell exhaustion and barrier defects.
• Prediction 3: Supplementing methyl donors (e.g., methionine or choline) will rescue the hypomethylation induced by rapamycin, restoring the methylation pattern without reversing mTORC1 inhibition, demonstrating that methylation changes are downstream of SAM availability.
• Prediction 4: Human colonic biopsies from patients with inflammatory bowel disease will show a methylation signature at these CpG sites that aligns with tissue mTORC1 activity (measured by p‑S6 staining) and predicts disease‑related acceleration of biological age beyond what blood‑based clocks capture.

Experimental Approach

1. Mouse models – Use inducible, intestinal epithelial‑specific Raptor KO (to inhibit mTORC1) and TSC1 KO (to activate mTORC1) mice. Collect colonic crypts at young, middle, and old ages.
2. Metabolomics – Quantify intracellular methionine, SAM, and SAH levels via LC‑MS/MS.
3. Epigenomics – Perform targeted bisulfite sequencing of the selected CpG panel; compare methylation beta‑values across conditions.
4. Functional readouts – Assess crypt proliferation (Ki‑67), apoptosis (cleaved caspase‑3), barrier integrity (FITC‑dextran assay), and stem cell colony‑forming efficiency.
5. Human validation – Obtain colonoscopy biopsies from IBD patients and controls; measure p‑S6 (mTORC1 activity), SAM levels, and CpG methylation; correlate with clinical disease scores and epigenetic age acceleration.

Falsifiability

If manipulation of mTORC1 activity fails to produce consistent, directional changes in SAM levels and methylation at the proposed CpG sites—or if methylation changes do not correspond with functional alterations in proliferation or barrier function—the hypothesis would be falsified. Conversely, a clear, reproducible link would establish mTORC1‑driven one‑carbon metabolism as a mechanistic bridge between nutrient signaling and a tissue‑specific epigenetic clock for the colon.

Implications

Confirming this model would provide a concrete molecular basis for viewing mTOR as a "civilization‑versus‑survival dial" in the gut: high mTORC1 drives anabolic, tissue‑building programs that are mirrored by a methylation pattern reflecting youthful metabolic states, whereas low mTORC1 shifts cells toward a survival, catabolic state accompanied by a distinct epigenetic signature. Such a clock could revolutionize how we assess gut‑targeted interventions, from rapamycin analogs to dietary regimens, by offering a direct readout of colonic biological age rather than relying on surrogate systemic measures.